Literature DB >> 26880691

Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features.

Gerhard J Molderings1.   

Abstract

Systemic mast cell activation disease (MCAD) comprises disorders characterized by an enhanced release of mast cell mediators accompanied by a varying accumulation of dysfunctional mast cells. Within the last years, evidence has been presented that MCAD is a multifactorial polygenic determined disease with the KIT(D816V) mutation and its induced functional consequences considered as special case. The respective genes encode proteins for various signaling pathways, epigenetic regulators, the RNA splicing machinery, and transcription factors. Transgenerational transmission of MCAD appears to be quite common. The basics of the molecular mechanisms underlying predisposition of the disease, that is, somatic and germline mutations and the contribution of epigenetic processes have become identifiable. The aim of the present review is to present and discuss available genetic, epigenetic and epidemiological findings, and to present a model of MCAD pathogenesis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26880691     DOI: 10.1016/j.trsl.2016.01.001

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  8 in total

1.  Characterization of Mast Cell Activation Syndrome.

Authors:  Lawrence B Afrin; Sally Self; Jeremiah Menk; John Lazarchick
Journal:  Am J Med Sci       Date:  2016-12-16       Impact factor: 2.378

Review 2.  Mast Cell Activation Syndrome in COVID-19 and Female Reproductive Function: Theoretical Background vs. Accumulating Clinical Evidence.

Authors:  Dariusz Szukiewicz; Piotr Wojdasiewicz; Mateusz Watroba; Grzegorz Szewczyk
Journal:  J Immunol Res       Date:  2022-06-22       Impact factor: 4.493

3.  Siglec-8 as mast cell selective target: developing paradigms amidst inconvenient truths.

Authors:  Gerhard J Molderings
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-09-14       Impact factor: 3.000

4.  White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome.

Authors:  B Haenisch; G J Molderings
Journal:  Transl Psychiatry       Date:  2018-05-10       Impact factor: 6.222

5.  Health-related quality of life and health literacy in patients with systemic mastocytosis and mast cell activation syndrome.

Authors:  Rupert Conrad; Martin Mücke; Tobias Jürgen Schmidt; Julia Sellin; Gerhard J Molderings
Journal:  Orphanet J Rare Dis       Date:  2022-07-29       Impact factor: 4.303

Review 6.  Pharmacological treatment options for mast cell activation disease.

Authors:  Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-30       Impact factor: 3.000

7.  Case Report: Treatment of systemic mastocytosis with sunitinib.

Authors:  Gerhard J Molderings; Lawrence B Afrin; Hans-Jörg Hertfelder; Stefan Brettner
Journal:  F1000Res       Date:  2017-12-28

8.  Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome.

Authors:  Lawrence B Afrin; Leonard B Weinstock; Gerhard J Molderings
Journal:  Int J Infect Dis       Date:  2020-09-10       Impact factor: 3.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.